Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients

Journal of Nuclear Medicine

Volumn 39, Issue 12, 1998, Pages 2097-2104

  Wong, Jeffrey Y C ^a   Chu, David Z J ^a   Yamauchi, Dave ^a   Odom Maryon, Tamara L ^a   Williams, Lawrence E ^a   Liu, An ^a   Esteban, Jose M ^a   Wu, Anna M ^a   Primus, F James ^a   Beatty, J David ^a   Shively, John E ^a   Raubitschek, Andrew A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Carcinoembryonic antigen; Chimeric antibody; Indium 111; Protein dose; Radiolabeled antibodies

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY IN 111; CHIMERIC ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY T 84.66 IN 111; PENTETIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INDIUM RADIOISOTOPES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; METABOLIC CLEARANCE RATE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 0032438053     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
2. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993;68:403-406.
3. 111In anticarcinoembryonic antigen monoclonal antibody ZCE-025. Radiology 1987;164:617-621.
4. 111In labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial. J Nucl Med 1993;34:1656-1661.
5. Bischof-Delaloye A, Delaloye B. Diagnostic applications and therapeutic approaches with different preparations of anti-CEA antibodies. Int J Biol Markers 1992;7:193-197.
6. 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts. Cancer Res 1989;49:1587-1594.
7. Patt YZ, Lamki LM, Haynie TP, et al. Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J Clin Oncol 1988;6:1220-1230.
8. 111In MoAbs [Abstract]. Br J Cancer 1986;54:535.
9. 111In-labeled monoclonal antibody 96.5. Cancer Res 1985;45;2376-2381.
10. 111indium-labeled engineered human antibody CTM01 in ovarian cancer patients: influence of protein dose. Cancer Res 1997;56:5179-5185.
11. Boerman OC, Sharkey RM, Wong GY, Blumenthal RD, Aninipot RL, Goldenberg DM. Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. Cancer Immunol Immunother 1992;35:127-134.
12. Fenwick JR, Philpott GW, Connett JM. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (Mab) 1A3: the influence of administered Mab dose on tumor uptake. Int J Cancer 1989;44:1017-1027.
13. 131I-labeled anti-Thy 1.1 monoclonal antibody. Cancer Res 1985;45:1536-1544.
14. Bernstein ID, Eary JF, Badger CC, et al. High dose radiolabeled antibody therapy of lymphoma. Cancer Res 1990;50(suppl 3):10175-21s.
15. Hefta LJ, Wu AM, Neumaier M, Shively JE. Measuring antibody affinity using biosensors. In: Chiswell D, MacCafferty J, Moogenboom H, eds. Antibody engineering: a practical approach. London: Oxford Press; 1996:99-117.
16. 111indium. Nucl Med Biol 1990;17:247-254.
17. Neumaier M, Shively L, Chen FS, et al. Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human mouse T84.66 genes in myeloma and Chinese hamster ovary cells Cancer Res 1990;50:2128-2134.
18. 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a Phase I radioimmunotherapy trial. Cancer Res 1995;55(suppl 23):5929s-34s.
19. 111indium labeled anti-CEA chimeric monoclonal antibody (cT84.66). J Nucl Med 1997;38: 1951-1959.
20. Galen RS, Fink DJ. Probabilistic approaches to clinical decision support. In: Williams BT, ed. Computer aids to clinical decisions. Boca Raton, FL: CRC Press, Inc.; 1982:7-10.
21. Odom-Maryon TL, Chai A, Williams LE, et al. Pharmacokinetics modeling and absorbed dose estimation for a chimeric anti-CEA antibody (cT84.66) in humans J Nucl Med 1997;38:1959-1966.
22. Loevinger R, Berman M. MIRD pamphlet no. 1. (Supplement) J Nucl Med; 9:7-14.
23. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-546.
24. Williams LE, Primus FJ, Wong JYC, et al. Biodistribution of an In-111 or Y-90 labeled chimeric anti-CEA monoclonal antibody (cT84.66) following its large scale production in a bioreactor. Tumor Target 1996;2:116-124.
25. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3:213-233.
26. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;3:253-255.
27. Loevinger R, Japha EM, Brownell GL. Discrete radioisotope sources. In: Hine GJ, Brownell GL, eds. Radiation dosimetry. New York: Academic Press; 1956:823-824.
28. Halpern S, Hagan P. Effect of protein mass on the pharmacokinetic of murine monoclonal antibodies [Letter]. J Nucl Med 1985;26:818-819.
29. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 1996;2:1811-1818.
30. 131 labeled COL-1 in patients with gastroinestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacoknietics. J Clin Oncol 1996;6:1798-1809.
31. Corbisiero RM, Yamauchi DM, Williams LE, Esteban JM, Odom-Maryon T, Beatty JD. Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer, individual lesion analysis. Cancer Res 1991;51:5704-5711.
32. LoBuglio AF, Wheeler RH, Tranf J, et al. Mouse-human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86: 4220-4224.
33. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997;38:858-870.
34. Behr TM, Sharkey RM, Juweid MI, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res 1996;56:1805-1816.